A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management
Bevacizumab (Avastin(Ⓡ)) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. The known toxicities of bevacizumab are hypertension, proteinuria, wound healing complications, arterial thrombosis, bleeding, and gastrointestinal complications. Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed. Recently, a 65-year-old male patient developed ischemic pancolitis after FOLFOX (85 mg/m(2) Oxaliplatin, d1; 200 mg/m(2) Leucovorin, d1; 400 mg/m(2) 5-FU iv bolus, d1-2; and 600 mg/m(2) 5-FU, d1-2, every two wk) and Bevacizumab combination chemotherapy was administered. However, he recovered after early conservative care without surgery. We report this case with a review of literature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 58(2011), 1 vom: 19. Juli, Seite 42-6 |
| Sprache: |
Koreanisch |
|---|
| Beteiligte Personen: |
Lee, Ha Ni [VerfasserIn] |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 07.12.2011 Date Revised 12.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM210142278 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM210142278 | ||
| 003 | DE-627 | ||
| 005 | 20231224011117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||kor c | ||
| 028 | 5 | 2 | |a pubmed24n0700.xml |
| 035 | |a (DE-627)NLM210142278 | ||
| 035 | |a (NLM)21778803 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a kor | ||
| 100 | 1 | |a Lee, Ha Ni |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2011 | ||
| 500 | |a Date Revised 12.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Bevacizumab (Avastin(Ⓡ)) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with metastatic colorectal cancer. The known toxicities of bevacizumab are hypertension, proteinuria, wound healing complications, arterial thrombosis, bleeding, and gastrointestinal complications. Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed. Recently, a 65-year-old male patient developed ischemic pancolitis after FOLFOX (85 mg/m(2) Oxaliplatin, d1; 200 mg/m(2) Leucovorin, d1; 400 mg/m(2) 5-FU iv bolus, d1-2; and 600 mg/m(2) 5-FU, d1-2, every two wk) and Bevacizumab combination chemotherapy was administered. However, he recovered after early conservative care without surgery. We report this case with a review of literature | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Organoplatinum Compounds |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Lee, Myung Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Yejee |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hwayoung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hae Min |e verfasserin |4 aut | |
| 700 | 1 | |a Won, Hye Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, Sang Hoon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |d 2003 |g 58(2011), 1 vom: 19. Juli, Seite 42-6 |w (DE-627)NLM14272808X |x 2233-6869 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2011 |g number:1 |g day:19 |g month:07 |g pages:42-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2011 |e 1 |b 19 |c 07 |h 42-6 | ||